Your browser doesn't support javascript.
loading
[Chemoresistance in ovarian cancer. State of the art and future prospects]. / La chemioresistenza nel carcinoma dell'ovaio. Stato dell'arte e prospettive future.
Katsaros, D; Fracchioli, S; Arese, P; Enria, R; Cassinelli, P; Mingrone, K; Piccinno, R; Rigault de la Longrais, I A; Massobrio, M.
Afiliación
  • Katsaros D; Dipartimento di Discipline Ostetriche e Ginecologiche, Università degli Studi, Torino. dhocc@tin.it
Minerva Ginecol ; 51(12): 483-99, 1999 Dec.
Article en It | MEDLINE | ID: mdl-10767997
Aim of this study was to provide a review of the basic mechanisms of drug resistance in ovarian cancer and novel strategies to modulate drug resistance. Relevant articles published through August 1999 were identified using the Medline data base. Publications identified by the search were reviewed and evaluated critically for their relevance to drug resistance in ovarian cancer. Ovarian cancer patients have high response rates to initial chemotherapy after cytoreductive surgery. However, most will develop resistance to chemotherapy during the course of their treatment. There are multiple mechanisms resulting in drug resistance. Strategies to modulate drug resistance include dose intensity, various pharmacologic agents, and gene therapy.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: It Revista: Minerva Ginecol Año: 1999 Tipo del documento: Article Pais de publicación: Italia
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: It Revista: Minerva Ginecol Año: 1999 Tipo del documento: Article Pais de publicación: Italia